September 27, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX; OTC: ALGWF) (“Alliance Growers” or the “Company”) is pleased to announce that all local permits are in place for construction to commence at BiocannaTech, the Company’s wholly owned Quebec facility undertaking an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) application in Montreal, Quebec. Architectural design plans for the construction of the facility have been completed, permits received and demolition has commenced at the site on September 20, 2018.
The Health Canada ACMPR authorizes licenses required for cultivating and processing cannabis, the sale of cannabis for medical purposes and analytical testing and research in relation to cannabis. Applicants must clear a series of stages to ultimately receive such licenses. Now that the ACMPR “Ready to Build” stage has been reached by BiocannaTech, Alliance Growers President and CEO Dennis Petke and a delegation of Company executives and financiers were in Montreal last week and over the weekend to officially commence development of the BiocannaTech facility infrastructure.
As well, Alliance Growers management has leased the adjacent building for Phase 2 expansion. These two buildings are the only two locations in the Town of Mount Royal that are permitted for marijuana production. A moratorium on such further development within TMR has been recently implemented.
The progression of development at the BiocannaTech facility will take place in 3 phases:
Phase 1- 10,000 sq. ft existing facility
– Alliance Growers will provide financing and other resources to build out its wholly-owned subsidiary, BiocannaTech’s medical marijuana facility in the town of Mount Royal, Quebec, in preparation for the inspection from Health Canada.
– construction plans include a retro fit of the existing building that was previously used for cold storage. This is ideal as insulated panels are already in place.
– there is no need to allocate permanent space for a “mother” room as Alliance Growers will be providing plantlets to the facility from its Cannabis Biotech Complex in Deroche, BC.
– permits for construction are now in place, with estimated completion by December, 2018
– estimated license to produce for first cultivation targeted by January 31, 2019, with presales inspection by mid March 2019.
Phase 2- 17,000 expansion opportunity
– Alliance Growers has signed the lease to acquire another 17,000 square feet in a second building, including 15,000 for growing and 2,000 for existing offices, which includes a full loading/shipping dock.
– the second building is directly adjacent to the existing facility and can easily be connected to add more space and improve operating efficiency.
Phase 3- Additional ACMPR licenses in other Provinces
– After receiving the ACMPR in Quebec, Alliance Growers is planning an application for an ACMPR license in BC, and potentially Alberta as well.
Dennis Petke, President and CEO of Alliance Growers commented: “Thanks to our recent $2 Million financing, Alliance has shifted into high gear as it drives toward an ACMPR license in Quebec. A few members of the Alliance Team witnessed the initiation of demolition at the site on September 20, 2018. Receipt of all the necessary permits and the commencement of construction marks two additional bell weather milestones for the Company.
Alliance Growers has created a vertically integrated organization starting with the production of genetically perfect, disease free plantlets from the Cannabis Biotech Complex. This includes providing the plantlets for our own Licensed facilities and plantlets required for the production of 99% pure CBD oil derived from the CBD Dana Strain in a joint commercial hemp operation with Pharmagreen.
Additionally, future ACMPR production through BiocannaTech, the Company’s wholly owned subsidiary in Quebec, and other ACMPR investments will provide flower at wholesale cost for Cannabis CBD oil extraction to produce proprietary medical CBD oil protocols”
Mr. Petke commented further “The Company has begun planning the next round of financing, expected to commence October 17, 2018 with an anticipated closing date of November 30, 2018. Once again we thank our various stakeholders for their continued support as we build Alliance into a company poised to be a great success by setting up revenue generating projects that reflect the future of the cannabis market.”
About Alliance Growers Corp.
Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Biotech Complex, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. advancing a new business partnership, to jointly develop and operate a 62,000-square foot facility, to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The Cannabis Biotech Complex’s main facility is the Cannabis Biotech Centre which will grow Cannabis plantlets using proprietary tissue culture propagation, specifically utilizing the “Chibafreen Invitro Plant Production System”, which allows for more tissue cultured plantlets to be produced in less space and less time.
Through its wholly owned subsidiary, BioCannaTech Alliance is in the final expedited phase of Health Canada’s “Access to Cannabis for Medical Purposes Regulations” (ACMPR) approval for the production and sales of Medical Marijuana. BioCannaTech Inc. has a leased a 10,000 square foot facility in Mont-Royal, Québec with permits in place from the municipality to renovate the facility. Initial expansion plans include an adjacent 17,000 square foot facility, comprised of 15,000 square feet of growing space, and 2,000 square feet of existing offices and a full loading/shipping dock.
If you would like to be added to Alliance Growers’ news distribution list, please send your email address to email@example.com.
For more information contact:
CEO, President and Director
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.